Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214

In the randomized, open-label, phase 3 CheckMate 214 trial, nivolumab plus ipilimumab (nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 wk for four doses, then nivolumab 3 mg/kg every 2 wk) had superior efficacy over sunitinib (SUN; 50 mg once daily, 4 wk on, 2 wk off) in patients with untreated In...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Eur Urol
Asıl Yazarlar: Escudier, Bernard, Motzer, Robert J., Tannir, Nizar M., Porta, Camillo, Tomita, Yoshihiko, Maurer, Matthew, McHenry, M. Brent, Rini, Brian I.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2019
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7521478/
https://ncbi.nlm.nih.gov/pubmed/31732098
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eururo.2019.10.025
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller